Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2006-04, Vol.367 (9518), p.1247-1255
Hauptverfasser:	Harper, Diane M, Franco, Eduardo L, Wheeler, Cosette M, Moscicki, Anna-Barbara, Romanowski, Barbara, Roteli-Martins, Cecilia M, Jenkins, David, Schuind, Anne, Costa Clemens, Sue Ann, Dubin, Gary
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biopsy Cells Cervical cancer Cervical Intraepithelial Neoplasia - etiology Cervical Intraepithelial Neoplasia - prevention & control Cytology Deoxyribonucleic acid Diagnostics DNA Double-Blind Method Female Follow-Up Studies Humans Immunogenicity Lesions Multicenter Studies as Topic Papillomaviridae - immunology Papillomavirus Infections - complications Papillomavirus Infections - prevention & control Papillomavirus Vaccines Randomized Controlled Trials as Topic Safety Studies Time Factors Uterine Cervical Neoplasms - etiology Uterine Cervical Neoplasms - prevention & control Vaccines Viral Vaccines - adverse effects Viral Vaccines - classification Viral Vaccines - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!